211239 Implementing Personalized Medicine: Challenges and Opportunities for Healthcare Delivery and Policy

Tuesday, November 10, 2009: 2:30 PM

Amalia M. Issa, PhD, MPH , Program in Personalized Medicine and Targeted Therapeutics, University of Houston, Houston, TX
Delivering personalized medicine involves integrating genomics with other patient data in order to more coherently tailor therapeutics to patients. Personalized medicine is increasingly moving across the "translational interface" into the clinic. Many questions remain regarding how the translation of personalized medicine from basic science and clinical research to actual practice and health policies is going to be implemented in order to influence health care delivery.

In this presentation current scientific progress in the field and its potential clinical and policy impacts will be addressed and will provide a substantive overview for the invited panelists.

Learning Objectives:
Identify up-to-date “hot” areas in personalized medicine including current clinical applications. Evaluate the public health and policy-relevant implications of current personalized medicine research and clinical work. Describe how the public health community can address the challenges and opportunities presented by the emerging personalized genomic medicine applications.

Keywords: Genetics, Policy/Policy Development

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a professor and the Director of the Personalized Medicine & Targeted Therapeutics Initiative. I have extensive experience with this topic area including multiple publications.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Direct to consumer genetic testing and personalized medicine: What does it mean for the public’s health?
See more of: Genomics Forum